Upcoming regulatory changes to create new opportunity for specialized offerings.
Mark Trusheim
Advertisement
Articles by Mark Trusheim
Pharmaceutical Executive
An overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Advertisement
Latest Updated Articles
Improving Management of Gene and Cell TherapiesSeptember 10th 2018
Advertisement
Advertisement
Trending on PharmExec
1
What is it Like to Go From Treating Patients Directly to Running a Company?
2
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
3
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
4
Closing the Pediatric Evidence Gap
5